Production (Stage)
Entrada Therapeutics, Inc.
TRDA
$7.59
-$0.26-3.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -173.84% | 111.85% | -139.57% | 312.25% | 452.05% |
| Total Depreciation and Amortization | 1.28% | 34.78% | 12.35% | 24.66% | 72.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 121.05% | 19.06% | 6.67% | 65.34% | -32.64% |
| Change in Net Operating Assets | 49.94% | -1,316.42% | 79.44% | -63.14% | -124.95% |
| Cash from Operations | -50.90% | -687.57% | 0.92% | 213.51% | -112.55% |
| Capital Expenditure | -36.52% | 34.94% | 55.87% | 31.27% | 49.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -78.04% | 169.74% | -3,494.93% | 79.11% | 169.59% |
| Cash from Investing | -81.71% | 180.23% | -2,119.08% | 78.47% | 164.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 69.90% | 103.19% | -- | 22,781.94% | -98.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 69.90% | 103.19% | -102.99% | 22,781.94% | -98.95% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4,101.68% | 47.34% | -284.78% | 178.98% | -99.54% |